MCID: SYS050
MIFTS: 13

Systemic Lupus Erythematosus with Nephritis 2

Aliases & Classifications for Systemic Lupus Erythematosus with Nephritis 2

MalaCards integrated aliases for Systemic Lupus Erythematosus with Nephritis 2:

Name: Systemic Lupus Erythematosus with Nephritis 2 54
Systemic Lupus Erythematosus with Nephritis, Susceptibility to, 2 13

External Ids:

OMIM 54 607966

Summaries for Systemic Lupus Erythematosus with Nephritis 2

MalaCards based summary : Systemic Lupus Erythematosus with Nephritis 2, is also known as systemic lupus erythematosus with nephritis, susceptibility to, 2. An important gene associated with Systemic Lupus Erythematosus with Nephritis 2 is SLEN2 (Systemic Lupus Erythematosus With Nephritis 2). The drugs Cyclophosphamide and Mycophenolate mofetil have been mentioned in the context of this disorder. Affiliated tissues include b cells and bone.

Description from OMIM: 607966

Related Diseases for Systemic Lupus Erythematosus with Nephritis 2

Symptoms & Phenotypes for Systemic Lupus Erythematosus with Nephritis 2

Clinical features from OMIM:

607966

Drugs & Therapeutics for Systemic Lupus Erythematosus with Nephritis 2

Drugs for Systemic Lupus Erythematosus with Nephritis 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
2
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
3
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
4
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 134070 5280453
5 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Bone Density Conservation Agents Phase 4,Phase 2
9 Calcium, Dietary Phase 4,Phase 2
10 Micronutrients Phase 4,Phase 2
11 Trace Elements Phase 4,Phase 2
12 Vasoconstrictor Agents Phase 4,Phase 2
13 Vitamins Phase 4,Phase 2
14 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
15 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
16 Hormone Antagonists Phase 4,Phase 3,Phase 2
17 Hormones Phase 4,Phase 3,Phase 2
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
19 Adrenocorticotropic Hormone Phase 4
20 beta-endorphin Phase 4
21 Melanocyte-Stimulating Hormones Phase 4
22
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
23
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
24
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
25
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
26
Abatacept Approved Phase 2, Phase 3,Phase 1 332348-12-6 10237
27
Prednisone Approved, Vet_approved Phase 2, Phase 3, Phase 1 53-03-2 5865
28
Infliximab Approved Phase 2, Phase 3 170277-31-3
29 Antiemetics Phase 3,Phase 2
30 Anti-Inflammatory Agents Phase 3,Phase 2
31 Antineoplastic Agents, Hormonal Phase 3,Phase 2
32 Autonomic Agents Phase 3,Phase 2
33 Gastrointestinal Agents Phase 3,Phase 2
34 glucocorticoids Phase 3,Phase 2
35 Methylprednisolone acetate Phase 3,Phase 2
36 Methylprednisolone Hemisuccinate Phase 3,Phase 2
37 Neuroprotective Agents Phase 3,Phase 2
38 Peripheral Nervous System Agents Phase 3,Phase 2
39 Prednisolone acetate Phase 3,Phase 2
40 Prednisolone hemisuccinate Phase 3,Phase 2
41 Prednisolone phosphate Phase 3,Phase 2
42 Protective Agents Phase 3,Phase 2
43 Antibodies Phase 2, Phase 3,Phase 1
44 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
45 Antimetabolites Phase 2, Phase 3, Phase 1
46 Antimetabolites, Antineoplastic Phase 2, Phase 3, Phase 1
47 Autoantibodies Phase 2, Phase 3
48 Dermatologic Agents Phase 2, Phase 3
49 Immunoglobulins Phase 2, Phase 3,Phase 1
50 Pharmaceutical Solutions Phase 3,Phase 2

Interventional clinical trials:

(show all 34)

id Name Status NCT ID Phase Drugs
1 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
2 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
3 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
4 A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) Completed NCT00626197 Phase 3 corticosteroids;cyclophosphamide;mycophenolate mofetil;ocrelizumab;placebo
5 Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis Suspended NCT01773616 Phase 3 Oral prednisolone;Rituximab;Mycophenolate mofetil;Methyl prednisolone
6 TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) Terminated NCT00368264 Phase 2, Phase 3 infliximab;placebo
7 Study of LJP 394 in Lupus Patients With History of Renal Disease Terminated NCT00089804 Phase 3 abetimus sodium (LJP 394) and/or placebo solution;abetimus sodium (LJP 394);Phosphate-buffered saline
8 Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis Terminated NCT00430677 Phase 2, Phase 3 Corticosteroids (prednisone or prednisolone);Abatacept;Abatacept;Mycophenolate mofetil (MMF);Abatacept
9 CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis Withdrawn NCT02074020 Phase 3 Blisibimod;Placebo
10 Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis Withdrawn NCT00539799 Phase 3 prednisolone;Placebo
11 Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis Withdrawn NCT00336414 Phase 3 cyclophosphamide-prednisone-azathioprine
12 The Effect of Calcitriol on Progress and Activity of Lupus Nephritis Unknown status NCT01863641 Phase 2 calcitriol;placebo
13 Effect of Mesenchymal Stem Cell Transplantation for Lupus Nephritis Unknown status NCT00659217 Phase 1, Phase 2
14 Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE) Unknown status NCT00698191 Phase 1, Phase 2
15 Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus Completed NCT00556192 Phase 2 rituximab
16 Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) Completed NCT00094380 Phase 1, Phase 2 CTLA4-IgG4m (RG2077);Cyclophosphamide
17 Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study Completed NCT00976300 Phase 2 Cyclosporine A;Cyclophosphamide
18 Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis Completed NCT01085097 Phase 2 laquinimod;Mycophenolate Mofetil;prednisolone/prednisone;Placebo
19 Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus Completed NCT02021513 Phase 2
20 Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis Completed NCT00774852 Phase 2 abatacept;cyclophosphamide;azathioprine;prednisone;abatacept placebo;azathioprine placebo
21 Drug Therapy in Lupus Nephropathy Completed NCT00001212 Phase 2 prednisone;cyclophosphamide;cyclosporin A
22 Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE) Recruiting NCT01946880 Phase 2 Mycophenolate Mofetil;Hydroxychloroquine or Chloroquine;Prednisone
23 Etanercept for the Treatment of Lupus Nephritis Terminated NCT00447265 Phase 2 Etanercept;Lupus Treatment- Standard of Care;Placebo
24 Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST) Withdrawn NCT00230035 Phase 2 Rabbit anti-thymocyte globulin;Methylprednisolone;Growth colony stimulating factor (G-CSF);Corticosteroids;Mycophenolate mofetil;Azathioprine;Intravenous immunoglobulin;Methotrexate;Rituximab;Leflunomide
25 Study of LJP 394 (Abetimus Sodium) in Lupus Patients Withdrawn NCT00390091 Phase 2 abetimus sodium (LJP 394)
26 Humanized LL2IGG to Treat Systemic Lupus Erythematosus Completed NCT00011908 Phase 1 hLL2 (Epratuzumab)
27 Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis Completed NCT00818948 Phase 1 AMG 811
28 Cyclophosphamide and Fludarabine to Treat Lupus Nephritis Completed NCT00001676 Phase 1 SQ Fludarabine
29 Monoclonal Antibody Treatment for Systemic Lupus Erythematosus Completed NCT00046774 Phase 1 MRA 003 US
30 Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis Enrolling by invitation NCT03174587 Phase 1
31 Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases Terminated NCT00849745 Phase 1
32 Cyclophosphamide in Lupus Nephritis Unknown status NCT00441220
33 Anti-ficolin-2 Autoantibodies in Lupus Nephritis Completed NCT03063281
34 Detection of Annexin A2 in Systemic Lupus Erythematosus Not yet recruiting NCT03031925

Search NIH Clinical Center for Systemic Lupus Erythematosus with Nephritis 2

Genetic Tests for Systemic Lupus Erythematosus with Nephritis 2

Anatomical Context for Systemic Lupus Erythematosus with Nephritis 2

MalaCards organs/tissues related to Systemic Lupus Erythematosus with Nephritis 2:

39
B Cells, Bone

Publications for Systemic Lupus Erythematosus with Nephritis 2

Variations for Systemic Lupus Erythematosus with Nephritis 2

Expression for Systemic Lupus Erythematosus with Nephritis 2

Search GEO for disease gene expression data for Systemic Lupus Erythematosus with Nephritis 2.

Pathways for Systemic Lupus Erythematosus with Nephritis 2

GO Terms for Systemic Lupus Erythematosus with Nephritis 2

Sources for Systemic Lupus Erythematosus with Nephritis 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....